Abstract A 12-year-old Japanese boy who underwent kidney transplantation with a kidney from his mother developed severe proteinuria immediately after the operation. Because his original disease was nephrotic syndrome (focal segmental glomerulosclerosis, or FSGS) and electron microscopic examination of the renal biopsy showed foot process fusion, we diagnosed this as a recurrence of nephrotic syndrome to the transplanted kidney. Four months after the transplantation, posttransplant lymphoproliferative disorder (PTLD) developed, which was pathologically diagnosed as diffuse large B cell lymphoma. Treatment consisting of a reduction in immunosuppression resulted in improvement in PTLD a month after the start of treatment. However, relapse occurred 2 months after the first onset of PTLD, which we treated with rituximab (CD-20 monoclonal antibody 375 mg/m 2 ) once weekly for a total of four doses. The PTLD resolved immediately after the rituximab treatment was started, and, interestingly, urinary protein levels also improved at the same time. Three years later, the boy shows no signs of PTLD, and no proteinuria has been detected. These findings suggest that rituximab may be an effective treatment for recurrence of nephrotic syndrome after transplantation and that activated B cells may play a pivotal role in the recurrence of nephrosis after renal transplantation.
Introduction
Recurrence of nephrotic syndrome after renal transplantation in patients with focal segmental glomerulosclerosis (FSGS) is a major issue in renal transplantation. The recurrence rate is reported to be about 20% for transplanted FSGS patients [1, 2] . The prognosis for recurrent FSGS is poor, as approximately one-third of patients progress to end-stage renal failure within 5 years [3, 4, 5, 6, 7] . There have been case reports and case series of certain effective treatments for FSGS recurrence, such as oral cyclophosphamide therapy, high-dose cyclosporine therapy, treatment with ACE inhibitors or/and angiotensin receptor antagonists, plasma exchange, and immunoabsorption [3, 4, 8, 9] . It has recently been reported that about 70% of recurrent FSGS responded to high-dose cyclosporine A or a combination of high-dose cyclosporine A and therapeutic plasma exchange, but about 20% of those patients failed to respond to the therapy and lost their grafts because of recurrent FSGS [8] . Therefore, this remains an important issue.
Several reports have suggested that T cells are pathogenetically involved in the development of nephrotic syndrome [10] , but the role of B cells remains unclear. Some investigators have suggested that B cells may be involved in the pathogenesis of nephrotic syndrome [11, 12, 13, 14] , while Benz et al. recently reported that rituximab (anti-CD20 monoclonal antibody) treatment for steroid-dependent nephrotic syndrome with idiopathic thrombocytopenic purpura (ITP) induced a long-term remission in both nephrotic syndrome and ITP [15] . These findings suggest that activated B cells may play a pivotal role in nephrotic syndrome.
Posttransplant lymphoproliferative disorder (PTLD) is a severe complication in organ transplantation, and the use of strong immunosuppressants has increased the incidence of PTLD and its reportedly high mortality [16] . Recent reports have indicated that rituximab is effective for PTLD [17, 18, 19, 20, 21, 22] .
This report concerns a 12-year-old boy who suffered PTLD and recurrent nephrotic syndrome after renal transplantation and was treated with rituximab.
Case report
A 12-year-old boy who was serologically negative for Epstein-Barr virus (EBV) underwent kidney transplantation from his EBV-seropositive mother for end-stage renal failure due to sporadic FSGS. He was treated with tacrolimus (the target trough level was 15-20 ng/ml in the first 2 weeks and decreased to 10 ng/ml in the next 6 months), methylpredonisolone, and mizoribine after transplantation, but severe proteinuria was detected immediately after the transplantation. The renal biopsy specimen obtained 2 months after the transplantation showed minor glomerular abnormalities under light microscopy (Fig. 1a) , but electron microscopy indicated 60% foot process fusion (Fig. 1b) . We therefore diagnosed this case as recurrence of FSGS, but the urinary protein level decreased gradually without specific treatment for the recurrent disease.
Four months after the transplantation, the patient developed a posttransplant lymphoproliferative disorder (PTLD). His adenoids were swollen, and much bloody stool was detected because of multiple colon ulcers. The presence of the adenoid tumors and Fig. 1 Renal biopsy 2 months after transplantation (a, b) and 3 years after transplantation (c). a PAS staining shows minor glomerular abnormalities. b Electron microscopy indicates 60% foot process fusion. c No foot process fusion is detectable Fig. 2 Clinical course in terms of peripheral B cell counts, serum IgG levels, and ratio of urinary protein to urinary creatinine (U-P/U-Cr). a Peripheral B cells disappeared immediately after the rituximab treatment, while serum IgG levels decreased gradually. b Urinary protein decreased immediately after the rituximab administration colon ulcers led to a diagnosis of diffuse large B cell lymphoma, and in situ hybridization showed that those tumor cells were EBER-1 positive. In addition, real-time polymerase chain reaction detected 1.510 4 EBV genomes/mg DNA in the peripheral white blood cells (normal: <1.010 3 EBV genomes/mg DNA), and it was significantly higher than usual. Changing the immunosuppressant from tacrolimus to low-dose cyclosporine (the target cyclosporine level was 40-60 ng/ml) resulted in remission of PTLD. However, 2 months after the first onset of PTLD, adenoid swelling was observed again, which adenoid biopsy showed to be a recurrence of PTLD. Because the tumor cells were CD20-positive, we started treatment with 375 mg/m 2 of rituximab once weekly for a total of 4 doses. Fig. 2 shows the clinical course in terms of peripheral B cell counts, serum IgG levels, and the ratio of urinary protein to urinary creatinine (U-P/U-Cr). Immediately after the rituximab treatment was started, the adenoid tumors rapidly disappeared, B cells vanished from the peripheral blood, and the serum IgG level gradually decreased. Severe proteinuria (U-P/U-Cr was up to 8 mg/mg) was detected on the first day of transplantation (day 0 after the renal transplantation), and the serum albumin level was down to 2.6 mg/ dl, but U-P/U-Cr gradually decreased to <1.0 mg/mg within 3 months of the transplantation and serum albumin increased to 4.4 mg/dl. However, U-P/U-Cr rapidly increased to 2-3 mg/mg after the first onset of PTLD (around day 120), and serum albumin decreased to 2.9 mg/dl again. Diminishing proteinuria to a U-P/UCr level of nearly 1.0 mg/mg after the first remission of PTLD was achieved by reducing immunosuppression. The level was maintained for about 2 weeks, but the level increased again after the relapse of PTLD. Of special interest is that U-P/U-Cr decreased immediately after the rituximab administration, and serum albumin returned to normal, while the proteinuria disappeared completely 7 months after the treatment although the peripheral B cell count went up again.
After the rituximab treatment, EB viral DNA in the peripheral blood cells became undetectable. Three years after the rituximab treatment, no proteinuria has been detected, and the graft has been functioning well. The electron microscopic picture of the renal biopsy 3 years after transplantation, shown in Fig. 1c , shows no foot process fusion. The blood pressure has been effectively controlled, and the serum creatinine level fortunately remained below 1.0 mg/ dl throughout the entire clinical course.
We performed genetic analysis of podocin after obtaining the parents' informed consent, but no mutation was detected.
Discussion
Recurrence of nephrotic syndrome in patients with FSGS remains a major postrenal transplantation problem. In the case presented here, proteinuria was detected on the first day of transplantation because of the recurrence of nephrotic syndrome in the transplanted kidney. However, U-P/ U-Cr decreased gradually without any specific treatment for the recurrent disease. The reason for the spontaneous reduction in urinary protein was thought to be the effect of the immunosuppressants used to prevent rejection. However, U-P/U-Cr rapidly increased to 2 mg/mg after the development of PTLD, before reducing the immunosuppressants. During this clinical course, PTLD, through unknown mechanisms, may have contributed to the proteinuria increase associated with the recurrent disease. Interestingly, after the rituximab administration, urinary protein as well as peripheral B cells disappeared, suggesting that the activation of B cells may play a pathogenetic role in the recurrence of proteinuria or nephrotic syndrome after renal transplantation in FSGS patients.
The molecular link between the immune system and primary nephrotic syndrome remains unclear. It has been reported that T-cell hybridomas from nephrotic patients synthesize a factor or factors that produce transient proteinuria when injected into rats, suggesting that T-cell cytokines may induce the development of nephrotic syndrome [10] . Savin et al. reported the presence of circulating factor(s) with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis, although the factor or factors themselves have not been identified [23] . Because the glomerular permeability factor can be removed by immunoabsorption to a protein A column [11] and a nonprotein A anti-IgG affinity column (sheep antihuman antibody column) [12] , immunoglobulins or immunoglobulin-like substances may be involved in the recurrence of proteinuria or nephrotic syndrome after renal transplantation in FSGS patients. Kakumitsu et al. reported a case of nephrotic syndrome with intravascular B cell lymphomatosis, which they concluded might play an important role in the pathogenesis of nephrotic syndrome because the latter went into remission after the lymphomatosis treatment [13] . Kemper et al. observed T and B cell activation in childhood steroid-sensitive nephrotic syndrome and analyzed this activation by measuring the soluble IL-2 and low-affinity IgE receptors. They found that both T and B cell activities were elevated and suggested that steroid sensitive nephrotic syndrome is not only a T cell but also a B cell dysfunction [14] . Recently, Benz et al. found that anti-CD20 monoclonal antibody (rituximab) treatment for steroid-dependent nephrotic syndrome with ITP induced a long-term remission in both nephrotic syndrome and ITP [15] . Finally, in our case, urinary protein was elevated from the onset of diffuse large B cell lymphoma and decreased immediately after the B cells had disappeared, which suggests an important role for B cells in the pathogenesis of recurrent proteinuria or nephrotic syndrome after renal transplantation in FSGS patients.
Recently, strong immunosuppressants have increased the success rate of organ transplantation. However, such drugs may also increase the rate of PTLD, especially in pediatric EBV-seronegative recipients of organ transplantation. High mortality has been reported for PTLD, and treatment has been limited to the reduction of immunosuppression and the use of chemotherapy, surgical resection, antiviral therapy, and radiation [16] . Several investigators have reported that 20-50% of patients can be expected to recover as a result of reduction of immunosuppression [24, 25] . However, poor prognosis has been reported for cases with no response to such reduction of immunosuppression [24] . Recently, rituximab treatment has been shown to be effective for treating PTLD in adult [17, 18, 19] and pediatric patients [20, 21, 22] . The most common adverse reactions of rituximab are infusion-related fever, chills, or hives, but no side effects were seen in our patient. When reduction of immunosuppression is not effective, rituximab treatment is a rational alternative because most PTLD is induced by EBVtransformed CD20-positive B cells. Recent reports have stated that rituximab is also effective for idiopathic membranous nephropathy and lupus nephritis [26, 27] . Moreover, it is possible that rituximab treatment is effective for treating recurrent proteinuria or nephrotic syndrome after renal transplantation in FSGS patients. However, Weiss et al. have reported that rituximab was ineffective in three children with FSGS (two with recurrence in an allograft) [28] . Further studies are required to evaluate the role of rituximab in recurrent FSGS.
